FOCUS Webinar
We have watched SARS-CoV-2 develop for 18 months and have some idea of its trajectory. The Delta variant is the prime example of strains succeeding each other, becoming progressively worse in waves of infection. As the world moves into the second year of the Covid-19 pandemic, SARS-CoV-2 variants are now the fundamental issue at the root of many of our questions.

Will the vaccines work? Will we need new shots each year? Will the pandemic end or can we expect a renewed surge of Covid-19 cases every year, like we see with the flu? Understanding virus variation is critical to understanding how the pandemic will unfold and how Covid-19 may continue to affect our global economy, our societies, and all of us individually. Will the current decline in new infections in the United States, for example, be permanent or a case of seasonal population immunity?

What is known about viral evolution presents scenarios we are likely to encounter in the coming months and years. The Delta variant may mutates to a point of increased lethality, it might evade vaccines’ effectiveness, it could challenges antiviral treatments designed to prevent and treat disease or, eventually, it may become less harmful, similar to the four coronaviruses circulating today, such as the common cold.

These are some of the questions and issues at the heart of a new book “Variants! The Shape-Shifting Challenge of COVID-19” by William A. Haseltine, who will share his point of view about the current scenario and the near future during this webinar.

WHEN
  Thursday, November 11, 2021
  From 15:00 to 16:00 GMT+1
Speaker

William A. Haseltine
Keynote Speaker

William A. Haseltine PhD is a scientist, businessman, author and philanthropist. He was a professor at Harvard Medical School and Harvard School of Public Health from 1976-1993 where he was Founder and Chair of two academic research departments, the Division of Biochemical Pharmacology and the Division of Human Retrovirology. He is well known for his pioneering work on cancer, HIV/AIDS and genomics and, today, for his work on COVID-19. He has authored more than 200 manuscripts in peer reviewed journals and more than a dozen books, including six books on SARS-CoV-2 and the COVID-19 pandemic.
He is a pioneer in biotechnology having founded more than a dozen biotechnology companies in fields ranging from development of cutting edge pharmaceuticals to new materials and fuels. He is the Founder of Human Genome Sciences, Inc. and served as the Chairman and CEO of the company for twelve years.  Eight pharmaceutical products from companies he founded are currently approved by U.S. and international regulatory agencies.
William is currently Chair and President of ACCESS Health International, a foundation active in the United States, India, China, Singapore, and the Philippines (www.accessh.org). He is also Chairman of the Haseltine Foundation for Science and the Arts.
FEEDBACKS

star star star star star
81% Complete
star star star star star
13% Complete
star star star star star
6% Complete
star star star star star
0% Complete
star star star star star
0% Complete

Webinar

La sostenibilità oltre i bla bla bla

Webinar, December 16, 2021

"Si prega di non confondere il dire con il fare ed il fare con il risolvere". Questa massima dovrebbe essere presente sulle scrivanie di tutti i CEO...
Read more